Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Monsanto: The monsoon effect - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 15, 2002

    Monsanto: The monsoon effect

    The good Kharif season is reflected in the third quarter performance of Monsanto India. It may be noted that the company had merged three of its unlisted subsidiaries in May '00 last year. Thus the numbers for the current quarter are comparable on a like to a like basis. The benefit of restructuring excerise carried out by the company and good monsoon effect is reflected in the results. The company has recorded a 174% rise in PBT. Thanks to the new accounting policy on deffered taxation, there was a sharp jump in tax provision.

    (Rs m) 3QFY01 3QFY02 % change
    Sales 1,082 1,335 23.4%
    Other Income 7 7 4.3%
    Expenditure 964 1,035 7.3%
    Operating Profit (EBDIT) 117 300 156.3%
    Operating Profit Margin (%) 10.8% 22.5%  
    Interest 7 14 95.9%
    Depreciation 16 15 -1.3%
    Profit before Tax 101 278 174.4%
    Tax 13 94 655.2%
    Profit after Tax/(Loss) 89 183 106.7%
    Net profit margin (%) 8.2% 13.7%  
    No. of Shares (eoy) (m) 4.3 8.6  
    Diluted Earnings per share* 82.1 85.3  
    P/E (at current price) 5.4  
    (*- annualised)      

    The company has recorded a 174% rise in PBT. Thanks to the new accounting policy on deffered taxation, there was a sharp jump in tax provision. Monsanto had declared a loss in second quarter of the current year due to a sharp change in product mix.

    The integration of the company with its subsidiaries last year has resulted in a wide product portfolio consisting of herbicides, seeds and biotechnology products. Further, the company also carried out an expansion of its installed capacity of its formulations plant at Silvassa.

    Monsanto's chief strength has been its focus on the fast-growing herbicides segment thanks to the leadership status enjoyed by its parent in this business. The company's operating margins are amongst the best in the industry. The world market for agrochemicals is primarily dominated by herbicides, which forms 47% followed by insecticides at 32% and fungicide at 21%. By contrast, in the Indian agrochemicals market, insecticides have the lion's share of 76%, followed by herbicides with 13%. This is because insecticides are cheaper than herbicides. However, the consumption of agrochemicals is expected to move in favour of herbicides over a period of time, with steady increase in rural labour costs. This is because though insecticides are cheaper they incur higher labour cost. Further, with MNCs phasing out technical manufacturing in some parts of the world due to environmental reasons and relocating to Asian and African countries, multinational players in India, like Monsanto have better export opportunities.

    The stock is currently, trading at Rs 462, implying a P/E of 6x its 9mFY02 annualised earnings. The longer term outlook of the company looks encouraging considering the fact that internationally the company is one of the pioneers in biotech business. Going forward, the company is likely to benefit from new product introductions from the parent company.



    Equitymaster requests your view! Post a comment on "Monsanto: The monsoon effect". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in MONSANTO INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Detailed Financial Information With Charts